Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628780 | 0.88 | TRPM8 (0.78) | TRPM8POLBLMNAKMT2ATRPV1 | |
| Acoltremon SCHEMBL619824 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL14811473 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL2575067 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL23198293 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL23870506 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL17104729 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL3228667 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL16227989 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 | |
| Acoltremon SCHEMBL29570327 | 0.86 | TRPM8 (1.00) | TRPM8POLBALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656144-B2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | TRPM8 28/4885POLB 3043/4885ALDH1A1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.